iShares US Pharmaceuticals ETFIHE
IHE
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
4% less capital invested
Capital invested by funds: $359M [Q4 2024] → $345M (-$13.9M) [Q1 2025]
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
3% less funds holding
Funds holding: 154 [Q4 2024] → 149 (-5) [Q1 2025]
3.27% less ownership
Funds ownership: 59.13% [Q4 2024] → 55.86% (-3.27%) [Q1 2025]
21% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 43
Research analyst outlook
We haven’t received any recent analyst ratings for IHE.
Financial journalist opinion
Neutral
Zacks Investment Research
4 weeks ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
The iShares U.S. Pharmaceuticals ETF (IHE) was launched on 05/01/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
Positive
Seeking Alpha
1 month ago
IHE: Healthcare Dashboard For June
The healthcare providers industry is undervalued by about 22% versus 11-year averages, while pharma/biotech and life science tools trade near historical baseline in valuation. IHE ETF offers exposure to U.S. pharmaceuticals, with 47% of assets in Eli Lilly and Johnson & Johnson, posing significant concentration risk. IHE has lagged XLV in long-term returns but outperformed over the past 12 months, offering sufficient liquidity for both investors and traders.
Neutral
Seeking Alpha
2 months ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Positive
Zacks Investment Research
2 months ago
ETFs on the Move Post U.S.-China Trade Deal
Let's delve into the ETF world following the 90-day U.S.-China trade deal.
Negative
Zacks Investment Research
2 months ago
Pharma ETFs in Focus on Trump's Drug Price Overhaul
Trump's plan to slash the price of prescription drugs by 30% put pharma ETFs in focus.
Positive
Zacks Investment Research
2 months ago
A Look at Pharma ETFs After Strong Q1 Earnings
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
Negative
Benzinga
2 months ago
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility.
Neutral
Zacks Investment Research
3 months ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Launched on 05/01/2006, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Negative
Market Watch
3 months ago
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — President Donald Trump indicated he intends to roll out more product-specific tariffs down the road.
Negative
Market Watch
4 months ago
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector.
Charts implemented using Lightweight Charts™